TABLE 1.

Oral efficacy of ABT-773 against important respiratory and intracellular bacterial infections in mice^b

Bacterium and compound	MIC (μg/ml)	ED50a (95% confidence limits)
S. aureus 10649c
ABT-773	0.03	9.4 (6.0–14.8)
Clarithromycin	0.25	30.2 (20.9–43.8)
S. pneumoniae 6303d
ABT-773	0.001	10.0 (5.5–18.2)
Clarithromycin	0.008	37.3 (22.8–60.8)
S. pyogenes C203e
ABT-773	0.002	1.9 (1.1–3.3)
Clarithromycin	0.03	3.7 (2.3–6.1)
L. monocytogenes 2526f
ABT-773	0.03	100.1 (63.2–158.4)
Clarithromycin	0.12	>200 (NCg)

^aDosage (in milligrams per kilogram per day) required to protect 50% of the mice against inoculation with 100 times the LD₅₀. 

^bGroups of untreated mice showed 100% mortality. 

^cChallenge inoculum of log₁₀ 5.1. 

^dChallenge inoculum of log₁₀ 2.3. 

^eChallenge inoculum of log₁₀ 5.4. 

^fChallenge inoculum of log₁₀ 6.6. 

^gNC, not calculated.